Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

PREDICT: a clinical tool to decide when to include the pelvis in prostate cancer radiotherapy. Development and multicohort external validation.

Created on 15 Nov 2026

Authors

Agustin Rosich, Belem Cuervo, Joaquin Ferrer, Ester Sanchez, Pierina Debenedetti, Emiliano Rivero, Santiago Roldan, Federico Lorenzo

Published in

Practical radiation oncology. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

Decisions regarding elective pelvic irradiation in prostate cancer are often informed by the Roach formula, which uses only prostate-specific antigen (PSA) and Gleason score. We developed PREDICT to estimate individualized pretreatment dissemination risk from routine variables, evaluated nodal prediction externally and secondarily explored its implications for pelvic irradiation selection.
PREDICT was developed in 73 203 SEER patients diagnosed in 2018-2022, using age, PSA, Gleason pattern, biopsy cores and clinical stage, with nodal risk standardized to a 15-node dissection. Four predictor-specific versions fitted in SEER were applied without external refitting or imputation to four surgical cohorts (1923 patients; 106 node-positive). With pathologic nodal status as the reference, we estimated the threshold matching the sensitivity of the POP-RT criterion (Roach risk of 20% or more).
In 17 164 operated patients, the area under the curve (AUC) for nodal involvement was 0.793 with PREDICT versus 0.749 with Roach (paired difference, +0.043; 95% CI, +0.035 to +0.052), without a significant difference from MSKCC/Kattan. Externally, the paired difference versus Roach was -0.006 (-0.046 to +0.035). Observed nodal involvement increased from 1.6% to 25.1% across PREDICT risk bands in SEER and from 1.8% to 27.9% externally. In SEER, 15.3% (95% CI, 14.4% to 16.2%) matched POP-RT-criterion sensitivity with 7.0 fewer pelvic fields per 100 patients. This reduction was not demonstrated externally, and no common threshold was validated across populations.
PREDICT provides individualized pretreatment risk estimates to inform discussion of pelvic irradiation alongside clinical judgment. About 15% is a candidate threshold derived in SEER; threshold transportability and benefit from PREDICT-guided irradiation require prospective validation.

PMID:
43033911
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement